Successful Treatment of Severe Newly Diagnosed Immune Thrombocytopenia Involving an Alveolar Hemorrhage with Combination Therapy Consisting of Romiplostim, Rituximab and Vincristine
| Autor: | Masato Moriyama, Shukuko Miyakoshi, Ken Toba, Jun Takizawa, Yuji Matsuo, Yasuhiko Shibasaki, Tatsuo Furukawa, Ichiro Fuse, Kiyoshi Okazuka, Kyoko Fuse, Masayoshi Masuko, Tomoyuki Tanaka, Takashi Kozakai, Hironori Kobayashi |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
medicine.medical_specialty Vincristine Combination therapy Recombinant Fusion Proteins Hemorrhage Receptors Fc Severity of Illness Index Gastroenterology Antibodies Monoclonal Murine-Derived Pharmacotherapy hemic and lymphatic diseases Internal medicine Internal Medicine medicine Humans Thrombopoietin receptor Romiplostim business.industry Diffuse alveolar hemorrhage General Medicine Middle Aged Thrombocytopenia Pulmonary Alveoli Treatment Outcome Thrombopoietin Immunology Monoclonal Drug Therapy Combination Rituximab business medicine.drug |
| Zdroj: | Internal Medicine. 52:1239-1242 |
| ISSN: | 1349-7235 0918-2918 |
| Popis: | A 51-year-old man was admitted due to a severe bleeding tendency. After he was diagnosed with immune thrombocytopenia (ITP), several therapies, including steroids, steroid pulse, vincristine and rituximab, were administered; however, the patient's bleeding symptoms were not sufficiently controllable with these treatments. Subsequently, a diffuse alveolar hemorrhage was observed. Treatment with a thrombopoietin receptor agonist, romiplostim, was initiated to prevent lethal hemorrhaging, although the efficacy of thrombopoietic receptor agonists in such emergency situations has not been elucidated. The initiation of romiplostim achieved prompt remission in platelets. This case suggests that combination therapy with romiplostim, rituximab and vincristine is effective in cases of newly diagnosed severe therapy-resistant ITP. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|